Design Therapeutics (DSGN) Q1 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on GeneTAC® molecules for nucleotide repeat expansion diseases, with lead programs in Friedreich ataxia (FA), Fuchs endothelial corneal dystrophy (FECD), myotonic dystrophy type-1 (DM1), and Huntington's disease (HD).

• Lead FA candidate DT-216P2 advanced to Phase 1/2 after FDA clinical hold was lifted in December 2025; update on frataxin levels expected in H2 2026.

• FECD program (DT-168) completed Phase 1 and is in Phase 2 biomarker trial; DM1 candidate (DT-818) entered Phase 1 MAD trial with results anticipated in 2027.

• No product revenue to date; operations funded primarily through equity offerings.

Financial highlights

• Net loss for Q1 2026 was $17.6 million, compared to $17.7 million in Q1 2025.

• Operating expenses decreased to $19.7 million from $20.4 million year-over-year, driven by lower R&D costs in FA and FECD programs.

• Cash, cash equivalents, and investment securities totaled $222.8 million as of March 31, 2026, up from $219.8 million at year-end 2025.

• $19.9 million raised via at-the-market (ATM) equity offering in Q1 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations for more than 12 months from the reporting date.

• Anticipates increased expenses and operating losses as clinical and preclinical programs advance.

• Updates from RESTORE-FA and FECD Phase 2 trials expected in H2 2026; DM1 Phase 1 results anticipated in 2027.